MX337614B - Tratamiento de lupus nefritis usando laquinimod. - Google Patents

Tratamiento de lupus nefritis usando laquinimod.

Info

Publication number
MX337614B
MX337614B MX2012010070A MX2012010070A MX337614B MX 337614 B MX337614 B MX 337614B MX 2012010070 A MX2012010070 A MX 2012010070A MX 2012010070 A MX2012010070 A MX 2012010070A MX 337614 B MX337614 B MX 337614B
Authority
MX
Mexico
Prior art keywords
lupus nephritis
laquinimod
subject
treatment
treating
Prior art date
Application number
MX2012010070A
Other languages
English (en)
Other versions
MX2012010070A (es
Inventor
Nora Tarcic
Asi Haviv
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337614(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2012010070A publication Critical patent/MX2012010070A/es
Publication of MX337614B publication Critical patent/MX337614B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para tratar a un sujeto que padece de lupus nefritis activo que comprende administrar periódicamente al sujeto una cantidad de laqumimod o sal farmacéuticamente aceptable del mismo efectiva para tratar el sujeto. Esta invención también proporciona laquinimod o sal farmacéuticamente aceptable del mismo para uso al tratar a un sujeto que padece de lupus nefritis activo Esta invención proporciona además una composición farmacéutica que comprende una cantidad de laquinimod o sal farmacéuticamente aceptable del mismo para uso al tratar a un sujeto que padece de lupus nefritis activo.
MX2012010070A 2010-03-03 2011-03-02 Tratamiento de lupus nefritis usando laquinimod. MX337614B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33936310P 2010-03-03 2010-03-03
PCT/US2011/026879 WO2011109526A1 (en) 2010-03-03 2011-03-02 Treatment of lupus nephritis using laquinimod

Publications (2)

Publication Number Publication Date
MX2012010070A MX2012010070A (es) 2012-10-03
MX337614B true MX337614B (es) 2016-03-10

Family

ID=44531856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010070A MX337614B (es) 2010-03-03 2011-03-02 Tratamiento de lupus nefritis usando laquinimod.

Country Status (20)

Country Link
US (5) US8889661B2 (es)
EP (1) EP2542078B1 (es)
JP (3) JP2013521303A (es)
KR (3) KR20130006640A (es)
CN (1) CN102791130B (es)
AU (2) AU2011223692A1 (es)
BR (1) BR112012021905A2 (es)
CA (1) CA2791691A1 (es)
CL (1) CL2012002423A1 (es)
CO (1) CO6630082A2 (es)
EA (1) EA201290837A1 (es)
ES (1) ES2558556T3 (es)
IL (1) IL250357A0 (es)
MX (1) MX337614B (es)
NZ (1) NZ602510A (es)
PE (2) PE20181523A1 (es)
PH (1) PH12012501739A1 (es)
SG (2) SG10201501535UA (es)
WO (1) WO2011109526A1 (es)
ZA (1) ZA201207129B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1937642T3 (en) * 2005-10-19 2014-12-15 Teva Pharma Crystals of sodium laquinimod and the process for its preparation
EA018031B1 (ru) 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
PT2682120T (pt) 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
BR112012000568A2 (pt) * 2009-06-19 2015-10-06 Teva Pharma tratamento da esclerose múltipla com laquinimod
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
SI2542079T1 (sl) * 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
JP2014530821A (ja) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (en) * 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
JP2016513665A (ja) 2013-03-14 2016-05-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドの経皮製剤
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2019060662A1 (en) * 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II
AU2023229221A1 (en) * 2022-03-04 2024-08-15 Novartis Ag Use of iptacopan for the treatment of lupus nephritis

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4782155A (en) * 1986-03-19 1988-11-01 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
US5139878A (en) * 1991-08-12 1992-08-18 Allied-Signal Inc. Multilayer film constructions
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6395750B1 (en) * 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
AU2003243870B2 (en) * 2002-06-25 2008-11-20 Merck Frosst Canada Ltd 8-(biaryl) quinoline PDE4 inhibitors
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
PE20050232A1 (es) * 2003-06-25 2005-04-01 Elan Pharm Inc Metodo y composiciones para tratar la artritis reumatoide
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
CA2561164A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
WO2005122278A1 (ja) * 2004-06-10 2005-12-22 Konica Minolta Holdings, Inc. 有機半導体薄膜、有機半導体デバイス、有機薄膜トランジスタ及び有機エレクトロルミネッセンス素子
WO2006029036A2 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
ES2572811T3 (es) * 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2592154C (en) 2005-01-31 2014-03-18 Laboratoires Serono S.A. N-hydroxyamide derivatives and use thereof
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
DK1937642T3 (en) * 2005-10-19 2014-12-15 Teva Pharma Crystals of sodium laquinimod and the process for its preparation
CA2623879C (en) * 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
AU2007224228B2 (en) 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
KR20080112300A (ko) 2006-03-16 2008-12-24 제넨테크, 인크. Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
EA018031B1 (ru) * 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
WO2008021368A2 (en) * 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
AU2007284337B2 (en) * 2006-08-17 2012-07-19 University Of Chicago Treatment of inflammatory diseases
CA2673398A1 (en) 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
RS52888B (sr) * 2007-03-27 2014-02-28 Zymogenetics Inc. Kombinacija blys inhibicije i mikofenolat mofetila za lečenje autoimunog obolenja
EP2567699A1 (en) * 2007-07-11 2013-03-13 MediciNova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
PT2682120T (pt) * 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
PL2276740T3 (pl) 2008-04-28 2015-01-30 Actavis Group Ptc Ehf Ulepszony sposób wytwarzania pochodnych chinolino-3-karboksyamidowych
EP2318371A2 (en) * 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
TW201438738A (zh) * 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BR112012000568A2 (pt) * 2009-06-19 2015-10-06 Teva Pharma tratamento da esclerose múltipla com laquinimod
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
AU2010282948C1 (en) * 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
CN102781239B (zh) * 2010-03-03 2015-01-21 泰华制药工业有限公司 使用拉喹莫德治疗狼疮关节炎
SI2542079T1 (sl) * 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
KR20130041193A (ko) 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
KR20130092558A (ko) * 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
JP5396349B2 (ja) * 2010-08-10 2014-01-22 日立ビークルエナジー株式会社 二次電池
MX2013006464A (es) * 2010-12-07 2013-07-29 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.
JP2014521659A (ja) * 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
IN2014MN00333A (es) * 2011-07-28 2015-09-25 Teva Pharma

Also Published As

Publication number Publication date
JP2017165740A (ja) 2017-09-21
CA2791691A1 (en) 2011-09-09
KR20150135552A (ko) 2015-12-02
US20180140594A1 (en) 2018-05-24
EA201290837A1 (ru) 2013-05-30
US20110218179A1 (en) 2011-09-08
CL2012002423A1 (es) 2012-12-21
AU2016204466A1 (en) 2016-07-21
NZ602510A (en) 2014-11-28
KR20130006640A (ko) 2013-01-17
CN102791130B (zh) 2015-02-25
CN102791130A (zh) 2012-11-21
SG10201501535UA (en) 2015-04-29
US20150038508A1 (en) 2015-02-05
PE20130613A1 (es) 2013-06-23
PH12012501739A1 (en) 2017-08-23
MX2012010070A (es) 2012-10-03
JP2016128464A (ja) 2016-07-14
IL250357A0 (en) 2017-03-30
WO2011109526A1 (en) 2011-09-09
AU2011223692A1 (en) 2012-10-25
EP2542078B1 (en) 2015-10-07
US20170258780A1 (en) 2017-09-14
KR20160129093A (ko) 2016-11-08
US8889661B2 (en) 2014-11-18
JP2013521303A (ja) 2013-06-10
BR112012021905A2 (pt) 2015-09-29
HK1177878A1 (zh) 2013-08-30
SG183512A1 (en) 2012-09-27
US20170368053A1 (en) 2017-12-28
EP2542078A1 (en) 2013-01-09
ES2558556T3 (es) 2016-02-05
ZA201207129B (en) 2014-06-25
CO6630082A2 (es) 2013-03-01
EP2542078A4 (en) 2013-07-10
PE20181523A1 (es) 2018-09-24

Similar Documents

Publication Publication Date Title
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
PH12012501740A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
PH12015500719A1 (en) Gdf-8-inhibitors
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
MY168791A (en) Carbamate compounds and of making and using same
MX369385B (es) Productos para cicatrizar heridas tisulares.
EA033374B9 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
IN2015DN03219A (es)
PH12013501688A1 (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells
MX360030B (es) Metodos para tratar el trastorno bipolar.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
TW201129361A (en) Methods for treating pain
WO2014028397A3 (en) Laquinimod for treatment of gaba mediated disorders
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
GB201115977D0 (en) Neurodevelopmental disorders
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.

Legal Events

Date Code Title Description
FG Grant or registration